Latest The Calmer Co International (ASX:CCO) News

The Calmer Co. has locked in an exclusive global distribution agreement for its kava extract ingredients, underpinning a potential A$25 million revenue stream over three years across key markets including the US and ASEAN.

The Calmer Co. has pushed back the closing date of its $3.5 million renounceable entitlement offer to give shareholders more time to participate, including those overseas.

The Calmer Co. has secured a long-term supply agreement for premium noble kava from Papua New Guinea and Vanuatu, underpinning its manufacturing growth and diversified Pacific sourcing network.

The Calmer Co. has signed a binding heads of agreement with Kaiming Agro Processing to establish a long-term manufacturing partnership, leveraging advanced extraction technology in Fiji to scale its premium botanical ingredients business globally.

The Calmer Co International Ltd is raising up to $3.5 million through a 1-for-1 renounceable entitlement offer priced at $0.001 per share, including free attaching options exercisable at $0.002. The capital will fund debt repayment, inventory expansion, marketing, and product launches.

The Calmer Co. has won Coles' approval for its innovative Fiji Kava® FZZR™ product, extending its Australian supermarket reach while gearing up for a broader U.S. retail rollout supported by a key brokerage partnership.

The Calmer Co. International Limited’s Fiji subsidiary has secured a FJ$548k non-repayable grant to expand ready-to-drink production and upgrade supply chain infrastructure, accelerating its growth without diluting shareholder equity.

The Calmer Co has posted a record $2.01 million in sales for Q2 FY26, propelled by a 9% increase in US revenue which now accounts for over half of the group’s total income. Strong retail and wholesale growth underpin the company’s expanding footprint in the natural relaxation market.

The Calmer Co. International Limited has reported a second consecutive quarter of revenue exceeding $2 million, driven by strong U.S. growth and record monthly sales in December. The company’s strategic focus on wholesale and B2B extract channels underpins its confidence in reaching breakeven this fiscal year.

A few stocks did the heavy lifting this week, with one biotech exploding higher and a gas name collapsing on the other side of the ledger. Big moves came from capital raises, regulator decisions, and drill results that investors treated as near-term value, not distant promises.

The Calmer Co. International Limited has reported its highest ever monthly sales of $910,767 in December 2025, driven by strong wholesale growth and expanding US market presence.

The FDA’s recent ruling classifying traditionally prepared kava beverages as food under U.S. law clears a major regulatory hurdle for The Calmer Co, accelerating its growth on Amazon and strengthening its U.S. expansion strategy.